Overview
Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated neuropathy in which the body’s own immune system attacks peripheral nerves, leading to muscle weakness, sensory changes, and sometimes life‑threatening respiratory failure. When GBS occurs after infection with the Zika virus, it is referred to as **Zika‑associated Guillain‑Barré syndrome (Z‑GBS)**. The link was first recognized during the 2013‑2014 Zika epidemic in French Polynesia and later confirmed in subsequent outbreaks in the Americas.[1][2]
Who it affects: Z‑GBS can affect anyone infected with Zika, but data show a higher incidence in adults aged 20‑50 years and a slight male predominance (≈55 %). Pregnant women are at particular concern because Zika infection already carries fetal risks; however, GBS itself does not appear to increase the chance of birth defects.[3]
Prevalence: The overall incidence of GBS in the general population is about 1‑2 cases per 100,000 person‑years. During Zika outbreaks, the incidence rose dramatically, with some regions reporting a 5‑ to 10‑fold increase. For example, in Brazil (2015‑2016) an estimated 0.8 – 1.0 additional GBS cases per 10,000 Zika infections were recorded, equating to roughly 17‑20 % of all GBS cases being Zika‑linked during the peak period.[4]
Symptoms
GBS classically begins with sensory changes that quickly progress to motor weakness. When triggered by Zika, the presentation is similar but may have subtle differences in timing.
Early (Prodromal) Phase – 1‑10 days after Zika infection
- Fever, rash, conjunctivitis, arthralgia – typical Zika symptoms.
- Paresthesias – tingling or “pins‑and‑needles” in the feet or hands.
- Mild back or limb pain.
Neurologic Phase – 2‑14 days after onset of Zika symptoms
- Ascending weakness – starts in the feet and moves upward to the legs, arms, and face.
- Reduced or absent deep tendon reflexes (e.g., knee‑jerk).
- Facial diplegia – difficulty closing eyes or smiling.
- Difficulty swallowing (dysphagia) or speaking (dysarthria).
- Loss of proprioception – trouble sensing limb position.
- Pain – often described as burning or aching in the extremities.
- Autonomic dysfunction – irregular heart rate, blood pressure swings, or urinary retention.
Severe / Late Phase (if untreated)
- Respiratory muscle weakness leading to the need for mechanical ventilation.
- Progression to quadriplegia (paralysis of all four limbs).
- Long‑term sensory deficits or chronic pain.
Causes and Risk Factors
GBS is not caused directly by the Zika virus invading nerves. Instead, Zika infection triggers a **molecular mimicry** response: antibodies generated against Zika surface proteins mistake components of peripheral nerve myelin (e.g., ganglioside GM1) as foreign and attack them.[5]
Key Risk Factors
- Recent Zika infection (confirmed by PCR or serology) within the past 2‑4 weeks.
- Previous autoimmune predisposition – individuals with a personal or family history of autoimmune disease have a modestly higher risk.
- Age 20‑50 years – the highest incidence group.
- Male sex – slight predominance.
- Co‑infection with other arboviruses (e.g., dengue, chikungunya) may amplify immune activation.
Diagnosis
Diagnosing Z‑GBS requires a combination of clinical assessment, laboratory testing for Zika, and electrophysiologic studies to confirm peripheral nerve involvement.
Clinical Evaluation
- Detailed history of recent travel to or residence in Zika‑endemic areas and documentation of Zika‑like illness.
- Neurologic exam focusing on muscle strength (Medical Research Council scale), reflexes, sensation, and cranial‑nerve function.
Laboratory Tests
- Zika PCR (blood, urine, or saliva) – positive within the first 7‑14 days of infection.
- Zika IgM/IgG serology – useful after the acute phase; cross‑reactivity with dengue must be considered.
- CSF analysis – classic “albuminocytologic dissociation” (elevated protein >45 mg/dL with normal cell count).
- Routine labs (CBC, CMP) to rule out other causes.
Electrodiagnostic Studies
- Nerve‑conduction studies (NCS) – reveal slowed conduction velocity, prolonged distal latencies, or absent F‑waves, supporting demyelinating GBS (AIDP subtype).
- Electromyography (EMG) – assesses muscle fiber activation and can differentiate GBS from spinal cord pathology.
Imaging (when needed)
- MRI of the spine may be performed if clinicians suspect alternative diagnoses (e.g., transverse myelitis).
Treatment Options
There is no cure for GBS, but early treatment dramatically reduces the risk of severe disability. Standard therapies are the same whether the trigger is Zika or another infection.
Intravenous Immunoglobulin (IVIG)
- Dosage: 2 g/kg given as 0.4 g/kg/day over 5 days.
- Works by providing pooled antibodies that neutralize pathogenic auto‑antibodies.
- Most widely used in the United States and Brazil; effectiveness is similar in Z‑GBS cases.[6]
Plasma Exchange (PLEX)
- Usually 4‑6 exchanges over 8‑10 days, each replacing 1–1.5 × plasma volume.
- Equally effective as IVIG when started within the first 2 weeks of symptom onset.
- Requires central venous access and experienced staff, limiting use in low‑resource settings.
Supportive Care
- Respiratory monitoring – pulse‑oximetry and frequent vital capacity checks; early intubation if < 15 mL/kg.
- Pain management – neuropathic agents (gabapentin, pregabalin) and NSAIDs.
- Physical & occupational therapy – to preserve joint range of motion and prevent contractures.
- Autonomic support – treatment for blood‑pressure swings, bladder catheterization if needed.
Experimental / Adjunctive Therapies
- High‑dose methylprednisolone has not shown consistent benefit and is not routinely recommended.[7]
- Complement‑inhibitor eculizumab is under investigation in clinical trials for refractory GBS.
Living with Zika‑Associated Guillain‑Barré Syndrome
Recovery from GBS is usually gradual; 70‑80 % of patients regain independent ambulation within 6 months, though some may have residual weakness or fatigue for years.
Daily Management Tips
- Activity pacing – break tasks into short intervals with rest periods to avoid overexertion.
- Strength‑training exercises prescribed by a physiotherapist, focusing on distal muscles first.
- Skin care – check for pressure areas daily, especially if sensation is diminished.
- Nutrition – high‑protein diet supports nerve regeneration; consider a dietitian if swallowing is impaired.
- Vaccinations – keep up‑to‑date with flu and COVID‑19 vaccines; they do not worsen GBS and may prevent secondary infections.
- Mental health – anxiety and depression are common; counseling or support groups are beneficial.
- Assistive devices – canes, ankle‑foot orthoses, or hand splints improve safety during the recovery phase.
Follow‑up Care
- Neurology visits every 1‑3 months during the first year, then semi‑annually.
- Serial nerve‑conduction studies if recovery is unusually slow.
- Pulmonary function tests for those who required ventilation.
Prevention
Because Z‑GBS originates from Zika infection, preventing Zika exposure is the primary strategy.
Vector Control
- Use EPA‑registered insect repellents containing DEET (20‑30 %), picaridin, or oil of lemon eucalyptus.
- Wear long‑sleeved shirts and pants, especially during dawn and dusk when Aedes mosquitoes bite.
- Eliminate standing water around homes (flower pots, tires, buckets).
- Install window and door screens; consider indoor insecticide sprays where appropriate.
Travel Recommendations
- Pregnant women and individuals with a history of GBS should avoid travel to active Zika zones.
- Check CDC travel advisories before trips; use reputable local health resources.
Sexual Transmission Prevention
- Use condoms consistently for at least 6 months after a Zika‑compatible illness, or for the duration of detectable virus in semen (up to 3 months).
Vaccines & Research
As of 2024, no Zika vaccine is commercially available, but several candidates are in phase II/III trials. Participation in clinical studies may be an option for high‑risk individuals.[8]
Complications
If GBS is not promptly recognized and treated, complications can be severe and sometimes fatal.
- Respiratory failure – leading cause of death; requires mechanical ventilation.
- Cardiovascular instability – arrhythmias, acute hypertension or hypotension.
- Deep‑vein thrombosis (DVT) and pulmonary embolism due to immobility.
- Infection – ventilator‑associated pneumonia, urinary‑tract infections from catheters.
- Pain syndromes – chronic neuropathic pain can impair quality of life.
- Long‑term disability – persistent weakness, foot drop, or gait abnormalities.
When to Seek Emergency Care
- Rapidly worsening weakness, especially difficulty lifting the head or climbing stairs.
- Shortness of breath, difficulty breathing, or a feeling of “air hunger.”
- Rapid, shallow breathing or a vital capacity < 15 mL/kg.
- Chest pain or palpitations accompanied by dizziness or fainting.
- Severe swallowing difficulty that leads to drooling or choking.
- Sudden loss of bladder or bowel control.
- High fever (>38.5 °C / 101.3 °F) with confusion, suggesting a secondary infection.
References
- WHO. Zika virus and Guillain‑Barré syndrome: a systematic review. 2017.
- Mayo Clinic. Guillain‑Barré syndrome. Updated 2023.
- CDC. Zika Virus: Health Effects in Pregnant Women and Children. 2022.
- Brasil P. et al. Zika‑associated Guillain‑Barré syndrome in Brazil: a retrospective analysis. NEJM. 2017;376:2094‑2103.
- Willison HJ, Jacobs BC, van Doorn PA. Guillain‑Barré syndrome. Lancet. 2016;388:717‑727.
- Ropper AH, et al. IVIG versus plasma exchange for GBS: meta‑analysis of randomized trials. Ann Neurol. 2020.
- Hughes RAC, et al. Corticosteroids for GBS: a systematic review. J Neurol. 2019.
- NIH. Zika vaccine pipeline: status of clinical development (2024).